JP2019534270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534270A5 JP2019534270A5 JP2019520036A JP2019520036A JP2019534270A5 JP 2019534270 A5 JP2019534270 A5 JP 2019534270A5 JP 2019520036 A JP2019520036 A JP 2019520036A JP 2019520036 A JP2019520036 A JP 2019520036A JP 2019534270 A5 JP2019534270 A5 JP 2019534270A5
- Authority
- JP
- Japan
- Prior art keywords
- dry powder
- powder according
- medicament
- weight
- dry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 claims 36
- 239000003814 drug Substances 0.000 claims 13
- 229940121375 antifungal agent Drugs 0.000 claims 10
- 239000003429 antifungal agent Substances 0.000 claims 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 6
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 6
- 206010017533 Fungal infection Diseases 0.000 claims 5
- 208000031888 Mycoses Diseases 0.000 claims 5
- 239000003381 stabilizer Substances 0.000 claims 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 210000002345 respiratory system Anatomy 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 3
- 239000011163 secondary particle Substances 0.000 claims 3
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 2
- 230000009798 acute exacerbation Effects 0.000 claims 2
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 2
- 235000011152 sodium sulphate Nutrition 0.000 claims 2
- 150000003852 triazoles Chemical group 0.000 claims 2
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 claims 1
- 201000002909 Aspergillosis Diseases 0.000 claims 1
- 208000036641 Aspergillus infections Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- 229960004130 itraconazole Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 150000004291 polyenes Chemical class 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408376P | 2016-10-14 | 2016-10-14 | |
| US62/408,376 | 2016-10-14 | ||
| PCT/US2017/056497 WO2018071757A1 (en) | 2016-10-14 | 2017-10-13 | Antifungal dry powders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534270A JP2019534270A (ja) | 2019-11-28 |
| JP2019534270A5 true JP2019534270A5 (enExample) | 2020-11-26 |
| JP7085538B2 JP7085538B2 (ja) | 2022-06-16 |
Family
ID=60186406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520036A Active JP7085538B2 (ja) | 2016-10-14 | 2017-10-13 | 抗真菌薬乾燥粉末 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11116722B2 (enExample) |
| EP (1) | EP3525759A1 (enExample) |
| JP (1) | JP7085538B2 (enExample) |
| KR (1) | KR102408798B1 (enExample) |
| CN (1) | CN109996536B (enExample) |
| AU (1) | AU2017341815B2 (enExample) |
| IL (1) | IL265913B2 (enExample) |
| MX (1) | MX388733B (enExample) |
| NZ (1) | NZ752353A (enExample) |
| RU (1) | RU2766086C2 (enExample) |
| WO (1) | WO2018071757A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4008326A1 (en) * | 2010-09-29 | 2022-06-08 | Pulmatrix Operating Company, Inc. | Monovalent metal cation dry powders for inhalation |
| WO2019204583A1 (en) * | 2018-04-18 | 2019-10-24 | Pulmatrix Operating Company, Inc. | Antifungal formulations for pulmonary administration comprising itraconazole |
| KR20210014629A (ko) * | 2018-04-18 | 2021-02-09 | 시플라 테크놀로지스 엘엘씨 | 진균 감염의 치료방법 |
| WO2021092349A1 (en) * | 2019-11-08 | 2021-05-14 | Scynexis, Inc. | Lipid-based formulations of scy-078 salts |
| CN111658610B (zh) * | 2020-07-31 | 2022-05-24 | 上海方予健康医药科技有限公司 | 一种供雾化器用的三氮唑类抗真菌药物的混悬液 |
| IT202000030437A1 (it) | 2020-12-10 | 2022-06-10 | Zambon Spa | Metodo per la realizzazione di una polvere inalabile comprendente voriconazolo |
| IT202000030443A1 (it) | 2020-12-10 | 2022-06-10 | Zambon Spa | Polvere inalabile comprendente voriconazolo in forma cristallina |
| WO2022187222A1 (en) * | 2021-03-03 | 2022-09-09 | Pulmatrix Operating Company, Inc. | Dihydroergotamine dry power formulations and methods of use |
| US20260158005A1 (en) * | 2021-11-09 | 2026-06-11 | Agency For Science, Technology And Research | A salt-based antifungal powder platform formulation for aerosolization |
| US20250049717A1 (en) * | 2021-12-20 | 2025-02-13 | Pulmatrix Operating Company, Inc. | Dry powder formulations of narrow spectrum kinase inhibitors |
| AU2023288123A1 (en) | 2022-06-21 | 2025-01-16 | Hovione Scientia Limited | Crystalline pharmaceutical composition for inhalation comprising sugar and lipid composite particles and process for manufacture |
| WO2024040175A1 (en) | 2022-08-18 | 2024-02-22 | Pulmatrix Operating Company, Inc. | Methods for treating cancer using inhaled angiogenesis inhibitor |
| EP4580632A2 (en) | 2022-08-31 | 2025-07-09 | Pulmatrix Operating Company, Inc. | Methods of using itraconazole dry powders |
| EP4780464A1 (en) * | 2023-09-20 | 2026-07-29 | The Board Of Trustees Of The University Of Illinois | Use of a dry powder inhaler to treat or prevent pulmonary fungal infections |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| US4097620A (en) | 1977-05-02 | 1978-06-27 | Xerox Corporation | Magnetic toner particle coating process |
| US4916134A (en) | 1987-03-25 | 1990-04-10 | Janssen Pharmacuetica N.V. | 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| US7473433B2 (en) * | 2000-12-21 | 2009-01-06 | Nektar Therapeutics | Pulmonary delivery of polyene antifungal agents |
| US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
| US6448401B1 (en) * | 2000-11-20 | 2002-09-10 | Bristol-Myers Squibb Company | Process for water soluble azole compounds |
| ITMI20010357U1 (it) | 2001-06-28 | 2002-12-30 | Plastiape Spa | Dispositivo inalatore |
| CA2511555A1 (en) | 2002-12-31 | 2004-07-22 | Nektar Therapeutics | Aerosolizable pharmaceutical formulation for fungal infection therapy |
| WO2005000267A2 (en) | 2003-05-28 | 2005-01-06 | Nektar Therapeutics | Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat |
| WO2005009375A2 (en) | 2003-07-22 | 2005-02-03 | Baxter International Inc. | Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| US8513204B2 (en) | 2004-06-21 | 2013-08-20 | Novartis Ag | Compositions comprising amphotericin B, mehods and systems |
| EP1789018A1 (en) | 2004-08-27 | 2007-05-30 | The Dow Chemical Company | Enhanced delivery of drug compositions to treat life threatening infections |
| GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| WO2007092088A1 (en) | 2005-12-28 | 2007-08-16 | Nektar Therapeutics | Compositions comprising amphotericin b |
| CN101495096A (zh) * | 2006-05-30 | 2009-07-29 | 伊兰制药国际有限公司 | 纳米微粒泊沙康唑制剂 |
| RU2413506C2 (ru) | 2006-08-11 | 2011-03-10 | Панацея Биотек Лимитед | Частицы для доставки активных ингредиентов, способ их получения и композиции из них |
| EP2227085A4 (en) | 2007-12-06 | 2013-10-09 | Berg Pharma Llc | INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY |
| EP2252275B1 (en) | 2008-02-13 | 2017-11-29 | Board of Regents, The University of Texas System | Templated open flocs of anisotropic particles for enhanced pulmonary delivery |
| EP2095816A1 (en) | 2008-02-29 | 2009-09-02 | Schlichthaar, Rainer, Dr. | Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety |
| EP2172193A1 (en) | 2008-10-02 | 2010-04-07 | Capsulution Nanoscience AG | Improved nanoparticulate compositions of poorly soluble compounds |
| WO2012030664A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| EP2723452A2 (en) | 2011-06-22 | 2014-04-30 | Vyome Biosciences Pvt Ltd | Conjugate-based antifungal and antibacterial prodrugs |
| EP2601973A1 (en) * | 2011-12-09 | 2013-06-12 | Laboratoires SMB SA | Dry powder formulation of azole derivative for inhalation |
| IN2012DE00674A (enExample) | 2012-03-07 | 2015-08-21 | Nat Inst Of Pharmaceutical Education And Res Niper | |
| WO2014106727A1 (en) | 2013-01-03 | 2014-07-10 | Vectura Limited | Inhaler and formulation |
| US20150366890A1 (en) | 2013-02-25 | 2015-12-24 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
| KR20150135328A (ko) * | 2013-04-01 | 2015-12-02 | 풀매트릭스 인코퍼레이티드 | 티오트로피움 건조 분말 |
| CN104398497B (zh) * | 2014-10-29 | 2017-11-24 | 中山大学 | 伊曲康唑吸入粉雾剂及其制备方法 |
| CA2972826C (en) * | 2015-01-14 | 2023-09-12 | Respira Therapeutics, Inc. | Powder dispersion methods and devices |
| WO2018195086A1 (en) | 2017-04-17 | 2018-10-25 | Respira Therapeutics, Inc. | Powder dispersion devices and methods |
-
2017
- 2017-10-13 US US16/341,152 patent/US11116722B2/en active Active
- 2017-10-13 IL IL265913A patent/IL265913B2/en unknown
- 2017-10-13 EP EP17791259.9A patent/EP3525759A1/en active Pending
- 2017-10-13 CN CN201780063648.5A patent/CN109996536B/zh active Active
- 2017-10-13 AU AU2017341815A patent/AU2017341815B2/en active Active
- 2017-10-13 RU RU2019114112A patent/RU2766086C2/ru active
- 2017-10-13 MX MX2019004322A patent/MX388733B/es unknown
- 2017-10-13 KR KR1020197013649A patent/KR102408798B1/ko active Active
- 2017-10-13 WO PCT/US2017/056497 patent/WO2018071757A1/en not_active Ceased
- 2017-10-13 NZ NZ752353A patent/NZ752353A/en unknown
- 2017-10-13 JP JP2019520036A patent/JP7085538B2/ja active Active
-
2023
- 2023-12-29 US US18/400,054 patent/US20240285523A1/en not_active Abandoned
-
2025
- 2025-02-13 US US19/052,958 patent/US20250221928A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013118453A (ru) | Катионы одновалентных металлов сухих порошков для ингаляций | |
| JP2013540123A5 (enExample) | ||
| JP6712231B2 (ja) | ニコチン粉末吸入器 | |
| AU2025204271A1 (en) | Microcrystalline diketopiperazine compositions and methods | |
| JP2021522161A5 (enExample) | ||
| RU2015146871A (ru) | Сухие порошки с тиотропием | |
| JP2016512494A5 (enExample) | ||
| RU2019114112A (ru) | Противогрибковые сухие порошки | |
| US20130028977A1 (en) | Pharmaceutical powder composition for inhalation | |
| JP2016515576A5 (enExample) | ||
| JP2013075909A (ja) | フォルモテロールを含むエアゾール | |
| CN103582477A (zh) | 包含芜地溴铵和皮质类固醇的组合 | |
| KR102355128B1 (ko) | 닌테다닙 또는 이의 약학적으로 허용가능한 염의 미세입자를 포함하는 흡입용 건조분말 제형 | |
| RU2018112077A (ru) | Направленная доставка высушенных распылением композиций в легкие | |
| CN116546980A (zh) | 用于肺部递送的药物组合物 | |
| US20200222412A1 (en) | Methods and compositions for treating pulmonary hypertension | |
| JP7592582B2 (ja) | 真菌感染症の治療に使用するための呼吸可能な乾燥粉末製剤 | |
| WO2012051050A1 (en) | Method for treating cystic fibrosis with inhaled denufosol | |
| ES2891346T3 (es) | Un proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico | |
| EP2821062A1 (en) | Novel dry powder inhaler formulations | |
| US20140377365A1 (en) | Sustained-release formulation of rotigotine | |
| CN102271689A (zh) | 氦-氧气体混合物用于治疗肺动脉高压的用途 | |
| CN103501791B (zh) | 用于通过吸入给药的改良皮质类固醇悬浮制剂 | |
| JP2017530988A5 (enExample) | ||
| CN104869996A (zh) | 阿地铵的新用途 |